755 related articles for article (PubMed ID: 9876028)
1. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and qualitative changes in serum luteinizing hormone after injectable testosterone undecanoate treatment in hypogonadal men.
Gu YQ; Ge ZY; Zhang GY; Bremner WJ
Asian J Androl; 2000 Mar; 2(1):65-71. PubMed ID: 11228940
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
4. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C
J Androl; 2006; 27(6):853-67. PubMed ID: 16837736
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
8. Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men.
Kornmann B; Nieschlag E; Zitzmann M; Gromoll J; Simoni M; von Eckardstein S
J Androl; 2009; 30(5):602-13. PubMed ID: 19342702
[TBL] [Abstract][Full Text] [Related]
9. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
10. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
Moisey R; Swinburne J; Orme S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
[TBL] [Abstract][Full Text] [Related]
11. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Saad F; Kamischke A; Yassin A; Zitzmann M; Schubert M; Jockenhel F; Behre HM; Gooren L; Nieschlag E
Asian J Androl; 2007 May; 9(3):291-7. PubMed ID: 17486268
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
[TBL] [Abstract][Full Text] [Related]
13. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
Behre HM; Abshagen K; Oettel M; Hübler D; Nieschlag E
Eur J Endocrinol; 1999 May; 140(5):414-9. PubMed ID: 10229906
[TBL] [Abstract][Full Text] [Related]
15. Effects of various modes of androgen substitution therapy on erythropoiesis.
Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
[TBL] [Abstract][Full Text] [Related]
16. Hypogonadal men treated with oral testosterone undecanoate.
Sarris S; Swyer GI; Lawrence DM
Acta Eur Fertil; 1977 Dec; 8(4):297-9. PubMed ID: 610314
[TBL] [Abstract][Full Text] [Related]
17. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester.
Behre HM; Nieschlag E
J Clin Endocrinol Metab; 1992 Nov; 75(5):1204-10. PubMed ID: 1430080
[TBL] [Abstract][Full Text] [Related]
18. [Effect of androgen on erythropoietin in patients with hypogonadism].
Cui YG; Tong JS; Pan QQ; Di FS; Jia Y; Feng T; Liu Y; Wang XH; Zhang GY
Zhonghua Nan Ke Xue; 2003; 9(4):248-51. PubMed ID: 12931361
[TBL] [Abstract][Full Text] [Related]
19. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
[TBL] [Abstract][Full Text] [Related]
20. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy.
Lanfranco F; Zitzmann M; Simoni M; Nieschlag E
Clin Endocrinol (Oxf); 2004 Apr; 60(4):500-7. PubMed ID: 15049966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
